| Attention deficit hyperactivity disorder
Jornay PM vs QuilliChew ER
Side-by-side clinical, coverage, and cost comparison for attention deficit hyperactivity disorder.Deep comparison between: Jornay Pm vs Quillichew Er with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQuillichew Er has a higher rate of injection site reactions vs Jornay Pm based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Quillichew Er but not Jornay Pm, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jornay Pm
Quillichew Er
At A Glance
Oral
Daily
CNS stimulant
Oral
Daily
CNS stimulant
Indications
- Attention deficit hyperactivity disorder
- Attention deficit hyperactivity disorder
Dosing
Attention deficit hyperactivity disorder 20 mg once daily orally in the evening (between 6:30 p.m. and 9:30 p.m.) as the starting dose for patients 6 years and older; titrate weekly in increments of 20 mg up to a maximum of 100 mg/day.
Attention deficit hyperactivity disorder Starting dose 20 mg once daily orally in the morning for patients 6 years and above; titrate weekly in increments of 10 mg, 15 mg, or 20 mg; doses above 60 mg/day have not been studied and are not recommended.
Contraindications
- History of hypersensitivity to methylphenidate or other components of JORNAY PM
- Concomitant treatment with monoamine oxidase (MAO) inhibitors, or within 14 days following discontinuation of an MAO inhibitor
- Hypersensitivity to methylphenidate or other components of QuilliChew ER
- Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days following MAOI discontinuation
Adverse Reactions
Most common (>=5%) Any insomnia, decreased appetite, headache, vomiting, nausea, psychomotor hyperactivity, affect lability or mood swings
Serious Hypersensitivity reactions (angioedema, anaphylaxis), hypertensive crisis with MAO inhibitors, serious cardiac events, psychiatric adverse reactions, priapism, peripheral vasculopathy including Raynaud's phenomenon, long-term suppression of growth in pediatric patients
Postmarketing Pancytopenia, thrombocytopenia, angina pectoris, bradycardia, severe hepatic injury, rhabdomyolysis, convulsion, serotonin syndrome, hallucinations, mania, priapism, alopecia, Raynaud's phenomenon
Most common (>=2%) Decreased appetite, aggression, emotional poverty, nausea, headache, weight decreased
Postmarketing Pancytopenia, thrombocytopenia, angina pectoris, severe hepatocellular injury, angioedema, anaphylactic reactions, convulsion, dyskinesia, serotonin syndrome, hallucination, mania, priapism, rhabdomyolysis, Raynaud's phenomenon
Pharmacology
CNS stimulant; methylphenidate is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space, though the exact mode of therapeutic action in ADHD is not known.
Methylphenidate is a CNS stimulant that blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space; the d-isomer is more pharmacologically active than the l-isomer.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jornay Pm
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (1/12)
Quillichew Er
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Jornay Pm
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (4/8) · Qty limit (4/8)
Quillichew Er
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Jornay Pm
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Quillichew Er
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Jornay Pm.
No savings programs available for Quillichew Er.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Jornay PmView full Jornay Pm profile
Quillichew ErView full Quillichew Er profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.